Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
Apremilast (Otezla®) is a relatively novel orally administered non-biologic disease-modifying anti-rheumatic drug (DMARD) extensively used in the management of psoriasis and psoriasis arthritis, lately approved for treating oral ulcerations in Behçets disease. Its advantageous side effect profile to...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-12-01
|
Series: | Case Reports in Dermatology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/511697 |